The economic implications of non-adherence after renal transplantation

被引:53
作者
Cleemput, I
Kesteloot, K
Vanrenterghem, Y
De Geest, S
机构
[1] Ctr Hlth Serv & Nursing Res, Louvain, Belgium
[2] Univ Hosp Leuven, Dept Nephrol, Louvain, Belgium
[3] Univ Basel, Inst Nursing Sci, Basel, Switzerland
关键词
D O I
10.2165/00019053-200422180-00006
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: The economic impact of therapeutic non-adherence in chronic diseases has rarely been examined using qualitative standards for economic evaluation. This study illustrates the impact of non-adherence on the cost utility of renal transplantation versus haemodialysis from the societal perspective and examines the scope for adherence-enhancing interventions. Methods: Long-term costs and outcomes in adherent and non-adherent renal transplant patients were simulated in a Markov model. The cost (euros, year 2000 values) and outcome data that were imputed in the model were derived from a prospective study in renal transplantation candidates performed in 2002. Probabilities of adverse events, graft rejection, graft loss and death in adherent and non-adherent renal transplant patients were derived from literature. Results: Compared with dialysis, renal transplantation offers a better outcome in both adherent and non-adherent patients. Lifetime costs after transplantation in the adherent patient group are higher than lifetime dialysis costs and lifetime costs in the non-adherent patient group, mainly because adherent patients live longer after transplantation. Long-term outcomes after transplantation are better for adherent than for non-adherent patients. The mean cost per QALY gained in adherent patients relative to non-adherent patients was euro35 021 per QALY (95% Cl 26 959, 46 620). Conclusion: Compared with established healthcare interventions, such as haemodialysis, renal transplantation can be considered a cost-effective therapy for patients with end-stage renal disease, even if patients are non-adherent after transplantation. The low incremental cost per QALY calculated in this model for adherent renal transplant patients, suggests there may be scope for adherence-enhancing interventions (provided that such interventions with a sufficiently high effectiveness exist or can be developed). As the findings are based on simulated long-term costs and outcomes, they should not be considered as precise estimates of the impact of non-adherence. This study is rather meant as an illustration of how non-adherence may impact on the results of cost-effectiveness analyses.
引用
收藏
页码:1217 / 1234
页数:18
相关论文
共 41 条
[1]  
BERNABEU M, 1993, TRANSPLANT P, V25, P17
[2]  
BITTAR AE, 1992, TRANSPLANT P, V24, P2720
[3]   EuroQol: The current state of play [J].
Brooks, R .
HEALTH POLICY, 1996, 37 (01) :53-72
[4]   VALUING THE FUTURE - TEMPORAL DISCOUNTING OF HEALTH AND MONEY [J].
CHAPMAN, GB ;
ELSTEIN, AS .
MEDICAL DECISION MAKING, 1995, 15 (04) :373-386
[5]   Economic implications of non-compliance in health care [J].
Cleemput, I ;
Kesteloot, K .
LANCET, 2002, 359 (9324) :2129-2130
[6]   A review of the literature on the economics of noncompliance. Room for methodological improvement [J].
Cleemput, I ;
Kesteloot, K ;
DeGeest, S .
HEALTH POLICY, 2002, 59 (01) :65-94
[7]  
CLEEMPUT I, 2004, EUR J HLTH EC
[8]  
Coambs RR., 1995, REV SCI LIT PREVALEN, P103
[9]   HOW OFTEN IS MEDICATION TAKEN AS PRESCRIBED - A NOVEL ASSESSMENT TECHNIQUE [J].
CRAMER, JA ;
MATTSON, RH ;
PREVEY, ML ;
SCHEYER, RD ;
OUELLETTE, VL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (22) :3273-3277
[10]  
CUTLER DM, 2001, HEALTH AFFAIR, V20, P11